Eli Lilly (NYSE:LLY) announced today that it acquired peptide- and protein-engineering platform developer Protomer Technologies.
Pasadena, Calif.-based Protomer Technologies develops next-generation protein therapeutics designed to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.
Get the full story at our sister site, Drug Delivery Business News.